drugset / Trial / NCT01218477
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-833923 | Small molecule | 50 mg | Oral |
| Subject | BMS-833923 | Small molecule | 100 mg | Oral |
| Subject | BMS-833923 | Small molecule | 200 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | Oral |